Genmab

2,015.00 DKK

-1.52 %

Less than 1K followers

GMAB

NASDAQ Copenhagen

Biotechnology & Pharmaceuticals

Health Care

Overview

Financials & Estimates

Investor consensus

-1.52 %

+5.00 %

+11.94 %

+35.78 %

+35.01 %

+31.18 %

-37.27 %

-16.01 %

+5,809.09 %

Genmab is a pharmaceutical company. The company specializes in the research and development of antibodies, which are mainly used in the treatment of cancer patients with lymphatic leukemia and solid tumors. Research and development are based on the company's own developed technology platform and operations are held on a global level. Genmab was founded in 1999 and is headquartered in Copenhagen, Denmark.

Market cap

129.44B DKK

Turnover

176.54M DKK

Revenue

21.53B

EBIT %

31.14 %

P/E

16.49

Dividend yield-%

-

Revenue and EBIT-%

Revenue B

EBIT-% (adj.)

EPS and dividend

EPS (adj.)

Dividend %

Financial calendar

5.2

2026

Annual report '25

19.3

2026

General meeting '26

7.5

2026

Interim report Q1'26

All

Research

Press releases

ShowingAll content types

Regulatory press release10 hours ago

Genmab Announces Completion of Tender Offer for Outstanding Common Shares of Merus N.V. and Commencement of Subsequent Offering Period

Press releaseyesterday

Genmab to Hold 2025 R&D Update and ASH Data Review Meeting

Press release12/8/2025, 9:30 PM

Genmab Announces New Data from Phase 1b/2 EPCORE® CLL-1 Highlighting Potential of Epcoritamab as Monotherapy and in Combination for Patients with Richter Transformation (RT)

Join Inderes community

Don't miss out - create an account and get all the possible benefits

Inderes account

Followings and notifications on followed companies

Analyst comments and recommendations

Stock comparison tool & other popular tools

HCA Morgenbørs 08/12 - Små fald i futures og fokus på Gubra, Genmab og Lundbeck

Video12/8/2025, 8:24 AM by

Michael Friis, Rasmus Køjborg

HCA Morgenbørs 08/12 - Små fald i futures og fokus på Gubra, Genmab og Lundbeck

I dagens Morgenbørs ser vi ind i små fald i de Europæiske futures afventede på FED. Herhjemme fokus på blandt andet Gubra, Lundbeck og Genmab.

Genmab Lundbeck Gubra MT Højgaard Holding AL Sydbank

Press release12/7/2025, 12:50 PM

Genmab Presents Pivotal Phase 3 Data from EPCORE® FL-1 Trial Demonstrating Clinical Benefit of EPKINLY® (epcoritamab-bysp) in Combination with Rituximab and Lenalidomide (R2) in Patients with Relapsed or Refractory Follicular Lymphoma

Press release12/6/2025, 2:30 PM

Genmab Announces Data From Multiple Clinical Trials Showing Treatment with Fixed-Duration Epcoritamab Led to Remissions in First-Line Diffuse Large B-Cell Lymphoma (DLBCL) and Follicular Lymphoma (FL)

Press release12/3/2025, 8:03 PM

Genmab Announces Closing of Private Offering of Senior Secured Notes and Senior Unsecured Notes

Regulatory press release12/1/2025, 9:24 PM

Transactions With Shares and Linked Securities in Genmab A/S Made by Managerial Employees and Their Closely Associated Persons

Press release11/24/2025, 12:00 PM

Genmab to Participate in a Fireside Chat at the Citi Global Healthcare Conference in Miami

Regulatory press release11/20/2025, 8:02 PM

Grant of Restricted Stock Units and Warrants to Employees in Genmab

Regulatory press release11/19/2025, 5:55 PM

Transactions with shares and linked securities in Genmab A/S made by managerial employees and their closely associated persons

HCA Morgenbørs 19/11 - Afventende markeder forud for Nvidia-regnskabet og fokus på NKT, Bioporto og Genmab

Video11/19/2025, 8:15 AM by

Rasmus Køjborg, Philip Coombes

HCA Morgenbørs 19/11 - Afventende markeder forud for Nvidia-regnskabet og fokus på NKT, Bioporto og Genmab

I dagens Morgenbørs ser vi ind i fortsat røde aktiemarkeder. Alle afventer Nvidia-regnskabet for Q3 2025 i aften efter markedets lukning i USA. Herhjemme fokus på bl.a. NKT, Bioporto og Genmab.

NKT Genmab BioPorto Føroya Banki

Press release11/18/2025, 9:01 PM

Genmab Announces Pricing of Private Offering of Senior Secured Notes and Senior Unsecured Notes and Completion of Syndication of New Senior Secured Term Loan Facility

Regulatory press release11/18/2025, 7:58 PM

Capital Increase in Genmab as a Result of Employee Warrant Exercise

Regulatory press release11/18/2025, 4:30 PM

Genmab Announces EPKINLY® (epcoritamab-bysp) in Combination with Rituximab and Lenalidomide Approved by the U.S. Food and Drug Administration for the Treatment of Relapsed or Refractory Follicular Lymphoma

HCA Morgenbørs 17/11 - Afventende futures og fokus på FLSmidth og GreenMobility

Video11/17/2025, 8:16 AM by

Michael Friis, Rasmus Køjborg

HCA Morgenbørs 17/11 - Afventende futures og fokus på FLSmidth og GreenMobility

I dagens Morgenbørs ser vi ind i blandede futures globalt og en afventende stemning forud for Nvidias regnskab og jobtal senere på ugen. Herhjemme er der fokus på GreenMobility og FLS.

FLSmidth & Co.SP Group NKT Lollands Bank BioPorto Nilfisk Holding Gabriel Holding Scandinavian Medical Solutions Danske Andelskassers Bank Møns Bank GreenMobility Ascelia Pharma Bavarian Nordic Genmab Tryg

Press release11/10/2025, 3:51 PM

Genmab Provides Certain Information Disclosed in Connection with Proposed Private Offering of Senior Secured Notes and Senior Unsecured Notes

Press release11/10/2025, 12:12 PM

Genmab Announces Proposed Private Offering of Senior Secured Notes and Senior Unsecured Notes and Syndication of New Senior Secured Term Loan Facility

HCA Morgenbørs 10/11 - Positive futures på mulig genåbning i USA og fokus på Novo Nordisk

Video11/10/2025, 8:09 AM by

Michael Friis, Rasmus Køjborg

HCA Morgenbørs 10/11 - Positive futures på mulig genåbning i USA og fokus på Novo Nordisk

I dagens Morgenbørs ser vi ind i et stort hop op i de amerikanske futures på en mulig amerikansk genåbning. Herhjemme er der blandt andet fokus på Novo Nordisk og Genmab.

Novo Nordisk ChemoMetec Genmab NTG Nordic Transport Group H+H International Wirtek FLSmidth & Co.Lundbeck Schouw & Co Matas Royal Unibrew ALK-Abelló Zealand Pharma Bavarian Nordic

HCA Morgenbørs 07/11 - Positive futures og fokus på Novo Nordisk, Bavarian, Gubra og Genmab

Video11/7/2025, 8:13 AM by

Michael Friis, Rasmus Køjborg

HCA Morgenbørs 07/11 - Positive futures og fokus på Novo Nordisk, Bavarian, Gubra og Genmab

I dagens Morgenbørs ser vi ind i positive futures efter gårsdagens nedtur. Herhjemme er der fokus på Novo, Bavarian, Gubra, Genmab og andre regnskabsaktuelle selskaber.

Novo Nordisk Bavarian Nordic Zealand Pharma Genmab Gubra Novonesis Torm DFDS Vestas Wind Systems DSV A.P. Møller - Mærsk

Inderes’ Disclaimer can be found here. Detailed information about each share actively monitored by Inderes is available on the company-specific pages on Inderes’ website. © Inderes Oyj. All rights reserved.